Market Overview

UPDATE: Stifel Nicolaus Initiates Buy with $72 PT on Mednax; Valuation Attractive

Share:
Related MD
Benzinga's Top Downgrades
After Rounds Of Financing, Is Healthcare M&A Picking Up?
Mednax (MD) Q1 2016 Results - Earnings Call Webcast (Seeking Alpha)

Stifel Nicolaus initiates its coverage on Mednax (NYSE: MD) with a Buy rating and a $72 price target.

Stifel Nicolaus comments, "We like the company's prospects for internal growth and acquisitions of neonatology and anesthesiology practices, and view the current valuation, at only the 14th percentile of historical forward P/E, as an attractive entry point. …Our Buy rating is based on an improving internal growth rate, an increasing pace of accretive acquisitions, and a current valuation well below the median (since 2004) forward P/E of 15.1x. The current valuation is at only 14th historical percentile. Our target price of $72, equal to a median multiple applied to our forward EPS estimate, implies 20% price appreciation."

MD closed at $60.01 on Monday.

Latest Ratings for MD

DateFirmActionFromTo
Mar 2016Stifel NicolausMaintainsBuy
Mar 2016SusquehannaDowngradesPositiveNeutral
Oct 2015SunTrust Robinson HumphreyMaintainsNeutral

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (MD)

View Comments and Join the Discussion!